华兰疫苗跌1.15% 2022年上市见顶募22.76亿元

Group 1 - The core point of the news is that Hualan Vaccine's stock has been underperforming since its IPO, currently trading at 18.87 yuan, down 1.15% [1] - Hualan Vaccine was listed on the Shenzhen Stock Exchange's ChiNext on February 18, 2022, with an initial public offering (IPO) of 40.01 million shares at a price of 56.88 yuan per share [1] - The stock reached a peak of 79.78 yuan on its first trading day but has since experienced a decline, currently in a state of loss [1] Group 2 - The total funds raised from the IPO amounted to 2.276 billion yuan, with net proceeds of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [1] - The actual funds raised were 251 million yuan less than the planned 2.495 billion yuan, which was intended for various vaccine development and production projects [1] - The total issuance costs for the IPO were 31.5657 million yuan, with Huatai United Securities receiving a total of 22 million yuan in underwriting and sponsorship fees [1] Group 3 - On May 30, 2023, Hualan Vaccine announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 5 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for June 6, 2023, with the ex-dividend date on June 7, 2023 [2]